Drug Trial Radar · NCT01272037
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
5,018
Actual
Start
Feb 28, 2011
Primary completion
Feb 1, 2023
Study completion Jan 8, 2027
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Jan 7, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized phase III clinical trial studies how well tamoxifen citrate, anastrozole, letrozole, or exemestane with or without chemotherapy work in treating patients with breast cancer that has spread from where it began in the breast to surrounding normal tissue (invasive). Estrogen can cause the growth of breast cancer cells. Hormone therapy, using tamoxifen citrate, may fight breast cancer by blocking the use of estrogen by the tumor cells. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, may fight breast cancer by lowering the amount of estrogen the body makes. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving tamoxifen citrate, anastrozole, letrozole, or exemestane is more effective with combination chemotherapy in treating patients with breast cancer.
Conditions
- Breast Ductal Carcinoma In Situ
- Invasive Breast Carcinoma
- Multicentric Breast Carcinoma
- Multifocal Breast Carcinoma
- Synchronous Bilateral Breast Carcinoma
Interventions
AnastrozoleDrug
Given PO
ExemestaneDrug
Given PO
Laboratory Biomarker AnalysisOther
Correlative studies
LetrozoleDrug
Given PO
Quality-of-Life AssessmentOther
Ancillary studies (closed as of 12/1/12)
Systemic ChemotherapyDrug
Given IV
Tamoxifen CitrateDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Invasive Disease-Free Survival (IDFS)Time frame: 5 years after randomization
Locations
1,568 sites in 10 countries. Site status is shown where the registry gives one.
Northeast Alabama Regional Medical Center
Anniston, Alabama
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama
Providence Hospital
Mobile, Alabama
University of South Alabama Mitchell Cancer Institute
Mobile, Alabama
Anchorage Associates in Radiation Medicine
Anchorage, Alaska
Anchorage Radiation Therapy Center
Anchorage, Alaska
Alaska Breast Care and Surgery LLC
Anchorage, Alaska
Alaska Oncology and Hematology LLC
Anchorage, Alaska
Alaska Regional Hospital
Anchorage, Alaska
Alaska Women's Cancer Care
Anchorage, Alaska
Anchorage Oncology Centre
Anchorage, Alaska
Katmai Oncology Group
Anchorage, Alaska
Providence Alaska Medical Center
Anchorage, Alaska
Fairbanks Memorial Hospital
Fairbanks, Alaska
Virginia G Piper Cancer Care-Del Camino
Scottsdale, Arizona
Mercy Hospital Fort Smith
Fort Smith, Arkansas
CHI Saint Vincent Cancer Center Hot Springs
Hot Springs, Arkansas
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
Jonesboro, Arkansas
NEA Baptist Memorial Hospital
Jonesboro, Arkansas
Kaiser Permanente-Anaheim
Anaheim, California
East Bay Medical Oncology Hematology Medical Associates-Antioch
Antioch, California
Kaiser Permanente-Deer Valley Medical Center
Antioch, California
PCR Oncology
Arroyo Grande, California
Sutter Auburn Faith Hospital
Auburn, California
Sutter Cancer Centers Radiation Oncology Services-Auburn
Auburn, California
Kaiser Permanente-Baldwin Park
Baldwin Park, California
Kaiser Permanente-Bellflower
Bellflower, California
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California
Mills-Peninsula Medical Center
Burlingame, California
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
Cameron Park, California
Mercy San Juan Medical Center
Carmichael, California
East Bay Radiation Oncology Center
Castro Valley, California
Eden Hospital Medical Center
Castro Valley, California
Valley Medical Oncology Consultants-Castro Valley
Castro Valley, California
Community Cancer Institute
Clovis, California
University Oncology Associates
Clovis, California
John Muir Medical Center-Concord
Concord, California
UC Irvine Health Cancer Center-Newport
Costa Mesa, California
Sutter Davis Hospital
Davis, California
Showing 40 of 1,568 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.